CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008

(2009) C. Verslype et al.   ANNALS OF ONCOLOGY

CIP2A Is Associated with Human Breast Cancer Aggressivity

(2009) C. Come et al.   CLINICAL CANCER RESEARCH

Bortezomib Overcomes Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway

(2009) Kuen-Feng Chen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation

(2009) Kuen-Feng Chen et al.   JOURNAL OF HEPATOLOGY

MYC-Dependent Regulation and Prognostic Role of CIP2A in Gastric Cancer

(2009) Anchit Khanna et al.   JNCI-Journal of the National Cancer Institute

Down-regulation of Phospho-Akt Is a Major Molecular Determinant of Bortezomib-Induced Apoptosis in Hepatocellular Carcinoma Cells

(2008) K.-F. Chen et al.   CANCER RESEARCH

CIP2A Is Overexpressed in Gastric Cancer and Its Depletion Leads to Impaired Clonogenicity, Senescence, or Differentiation of Tumor Cells

(2008) W. Li et al.   CLINICAL CANCER RESEARCH

Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

(2008) R. Z. Orlowski et al.   CLINICAL CANCER RESEARCH

Mechanisms of proteasome inhibitor action and resistance in cancer

(2008) David J. McConkey et al.   DRUG RESISTANCE UPDATES

New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings

(2008) Enrique M Ocio et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE